Verkazia: Ciclosporin/Cyclosporine A 0.1% Cationic Emulsion (CsA CE)

  • Lack of availability of a commercial preparation of topical CsA, technical difficulties in dispensing eye drops, and legal restrictions on its topical use in many countries have precluded widespread use in VKC1
  • Santen developed CsA CE 0.1% in order to increase the bioavailability of ciclosporin A at the ocular surface
    • Verkazia® is approved in the EU and Canada for the treatment of severe VKC in children from 4 years of age through adolescence2,3
    • This product is not approved for use in the US

1. Leonardi A et al. Ophthalmol Ther. 2013;2:73-88; 2. Verkazia (cyclosporine 0.1%). Product Monograph. Santen Incorporated; Emeryville, California. December 21, 2018; 3. Verkazia (ciclosporin 1 mg/mL). Summary of Product Characteristics. Santen Oy; Tampere, Finland. March 2, 2017.